|
Division of
Hematology Oncology
Alikhan MA, Carter G,
Mehta P. Topical GM-CSF
hastens healing of leg ulcers in sickle cell disease. Am J
Hematol 2004 Jun;76(2):192.
Alikhan MA, Kaushal V,
Mehta P, Spencer HJ, Kohli
M. Prognostic value of plasma vascular endothelial growth factor
in hormone-sensitive advanced stage prostate cancer: An
exploratory analysis. Proc of ASCO 23:4683, 2004.
Abstract.
Ambrosone
CB, Barlow W, Yeh I-T, Hayes DF, Davis W, Rae JM,
Hutchins LF,
Livingston R, Ravdin P, Martino S, Osborne K, Abeloff M, Lyss
AP, Albain K. (SWOG) Pharmacogenetics and breast cancer
treatment outcomes: results on oxidative stress-related
genotypes (MPO, MnSOD) from a southwest oncology group
intergroup trial (INT-01012). 29th Annual San
Antonio Breast Cancer Symposium, Breast Cancer Research and
Treatment. 2006 December 14-17; 100:37. Abstract.
Carter G,
Mehta P. Decreased erythropoietin usage in a VA
center using a model outreach program. Proc of ASH, 2005.
Abstract.
Coleman EA,
Hutchins L, Goodwin J. An overview of cancer in
the older adult. Medsurg Nurs 2004 Apr;13(2):75-80, 109;
quiz 81.
Eid AA, Hennings L, Caradine K,
Hodges A, Safar AM. Immature
vessel percentage (IVP) as a potential predictive factor for
anti-angiogenic therapeutics. Proc of ASCO 25(18S):21137,
2007. Abstract.
Eid A, Petty M,
Hutchins L, Thompson AR.
Breaking Bad News Standardized Patient Intervention (BBSPI)
Improves Hematology-Oncology Fellows’ and Advanced Practice
Nurses: Skills in Breaking Bad News. J Cancer Education
22(4)Supp:60, 2007. Abstract.
Ganz PA,
Hussey MA, Moinpour CM, Unger JM,
Hutchins LF,
Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late
cardiac effects of adjuvant chemotherapy in breast cancer
survivors treated on Southwest Oncology Group protocol s8897.J
Clin Oncol. 2008 Mar 10;26(8):1223-30. Epub 2008 Jan 28.
Gentry RW, Mehta J,
Safar M, Kyasa MJ, Thompson
R, Hester DM, Mehta P.
Disclosing prognosis when patients don’t ask. Fed Pract
2006;23(4):14-16, 33.
Gentry R, Mehta J, Hester M,
Thompson R, Mehta P. When is
the best time to refer to hospice? Federal Practitioner
2007; 11: 51-53.
Gentry RW,
Govindarajan R, Spencer HJ. The impact of lymph node
dissection in patients with colorectal cancer. Proc of ASCO
25(18S):17055, 2007. Abstract.
Gonzalez R,
Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of
Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16(6):521-6.
Govindarajan R,
Ratnasinghe L, Midathada M, Kim P,
Darbe M, Barnhart S, Siegel E, Simmons D, Kim L, Lang N.
Association between the use of thiazolidinediones and the risk
of cancer in diabetic patients. Proc of ASCO
23(16S):1005, 2005.Abstract.
Govindarajan R,
Parthasarathy S. Glycodelin: A possible new biological marker in
colorectal cancer. Proc of ASCO 24(18S):20081,
2006.Abstract.
Govindarajan R,
Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI.
Reversible posterior
leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY
43-9006. J Clin Oncol 2006; 24(28):e48.
Govindarajan R,
Siegel ER, Simmons DL, Lang NP. Thiazolidinedione (TZD) exposure
and risk of squamous cell carcinoma of head and neck (SCCHN).
Proc of ASCO 25(18S):1511, 2007. Abstract.
Govindarajan
R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L,
Kim PJ, Owens RJ, Lang NP. Thiazolidinediones and the risk of
lung, prostate, and colon cancer in patients with diabetes.
J Clin Oncol 2007; 25(12):1476-81.
Govindarajan
R, Young JW, Harless CL, Hutchins, LF. Barriers to clinical
trials vary according to the type of trial and the institution.
J Clin Oncol 2007; 25 (12):1633-4; 1634.
Greene GF, Gokden N,
Hutchins LF, Williams RC.
Metastatic renal cell carcinoma to prostate. Urology 2005
Jun;65(6):1227.
Hanna E, Alexiou M, Morgan J, Badley
J, Maddox AM, Penagaricano
J, Fan CY, Breau R, Suen J. Intensive chemoradiotherapy as a
primary treatment for organ preservation in patients with
advanced cancer of the head and neck: efficacy, toxic effects,
and limitations. Arch Otolaryngol Head Neck Surg 2004
Jul;130(7):861-7.
Hennings L,
Artaud C, Jousheghany F, Monzavi-Karbassi B,
Hutchins L, Kieber-Emmons T. Preclinical studies of carbohydrate mimetic
peptide vaccines for breast cancer. 29th Annual San
Antonio Breast Cancer Symposium, Breast Cancer Research and
Treatment. 2006 December 14-17; 100:1125. Abstract.
Hershman D,
Unger J, Barlow W, Hutchins L, Martino S, Abeloff M, Norton L,
Livingston R, Osborne K, Albain K. Treatment quality and outcome
of African American vs. European American breast cancer
patients: retrospective analysis of southwest oncology group
studies S8814/S8897. 29th Annual San Antonio Breast
Cancer Symposium, Breast Cancer Research and Treatment. 2006
December 14-17; 100:3049. Abstract.
Hutchins L,
Moon J, Clark J, Thompson J, Yost K, Sondak V. Interferon
alpha-2b and thalidomide in previously treated patients with
disseminated malignant melanoma: SWOG 0026. Proc of ASCO
23:7527, 2004. Abstract.
Hutchins LF,
Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP,
Allred C, Rivkin SE, Osborne CK. Randomized, controlled
trial of cyclophosphamide, methotrexate, and fluorouracil
versus cyclophosphamide, doxorubicin, and fluorouracil with
and without tamoxifen for high-risk, node-negative breast
cancer: treatment results of Intergroup Protocol INT-0102.
J Clin Oncol 2005 Nov 20;23(33):8313-21.
Hutchins LF,
Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak
VK. Evaluation of interferon alpha-2B and thalidomide in
patients with disseminated malignant melanoma, phase 2, SWOG
0026.Cancer. 2007 Nov 15;110(10):2269-75.
Joseph J, Rimawi A,
Mehta P, Cottler-Fox M,
Sinha A, Singh BK, Pacheco R, Smith ES 3rd, Mehta JL. Safety
and effectiveness of granulocyte-colony stimulating factor
in mobilizing stem cells and improving cytokine profile in
advanced chronic heart failure. Am J Cardiol 2006 Mar
1;97(5):681-4. Epub 2006 Jan 6.
Kapoor P,
Singh E, Radhakrishnan P, Mehta P. Splenectomy in plasma cell
dyscrasias: a review of clinical practice. Am J Hematol 2006; 81: 945-54.
Karri S, Carter G,
Safar A, Kyasa MJ, Mehta P.
Managing Erythropoeitin usage in a large Veterans healthcare
System. Proc of ASH. Blood Supplement Nov 16,2005;
106(11):2258. Abstract.
Karri S,
Doshi V. Hematological abnormalities in copper
deficiency. Blood 110(11): 2677, 2007.Abstract.
Karri S,
Govindarajan R, Bendure WB. Screening and genetic
counseling practices for hereditary non-polyposis colorectal
cancer (HNPCC). Proc of ASCO 25(18S):6564, 2007.
Abstract.
Khalil O,
Govindarajan R, Safar M, Hutchins L, Mehta P.
Clinical trial registration and the ICMJE. JAMA 2005 Jan
12;293(2):157; author reply 158.
Kaushal V, Kaushal GP,
Mehta P. Differential
toxicity of anthracyclines on cultured endothelial cells.
Endothelium 2004 Sep-Dec;11(5-6):253-8.
Kaushal V, Mehta P,
Gokden N, Kohli M, Dennis R A , Fink LM. ETS-1 and tissue
factor expression and regulation in PC-3 cells in vitro and in
prostate cancer in vivo. Proc of AACR, Mar 2005:4630.
Abstract.
Kaushal V,
Mehta P, Fink L. Tissue Factor and Factor VIIa
Regulate Expression of Ets-1 in Prostate Cancer,
International Society for Thrombosis and Haemostasis,
Sydney, Australia. August 2005. Abstract.
Keshava-Prasad H,
Kaushal V, Mehta P.
Effects of thalidomide on platelets in vivo and in vitro.
Blood 2006; 108:3969. Abstract.
Khalid AA, Morgan JE, Horace S,
Hanna EY, Breau R, Kyasa MJ, Maddox AM.
Early complications of organ preservation treatment in head and
neck cancer, UAMS experience. Proc of ASCO 23:5607, 2004.
Abstract.
Kohli M, Zent C,
Hutchins LF, Safar M, Dotson
P, Mehta P. The academic
hematology-oncology firm:a model for postgraduate cancer
education. J Cancer Educ. 2004 Spring;19(1):45-9.
Kota M,
Shah R, James J, Kohli M, Greene G,
Maddox AM. Cyclooxygenase-2 expression in renal cell
neoplasms. Proc of ASCO 23:9699, 2004. Abstract.
Kyasa MJ.
Phase II trial of Tamoxifen and interferon alpha
in patients with metastatic or recurrent soft tissue sarcoma.
Proc of ASCO 23:9031, 2004. Abstract.
Linden HM, Haskell CM, Green SJ,
Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D,
Hutchins
LF, Livingston RB, Martino S. Sequenced compared with
simultaneous anthracycline and cyclophosphamide in high-risk
stage I and II breast cancer: final analysis from INT-0137
(S9313). J Clin Oncol 2007; 25(6):656-61.
Ma Q, Safar
M, Holmes E, Wang Y, Boynton AL, Junghans RP.
Anti-prostate specific membrane antigen designer T cells for
prostate cancer therapy. Prostate Sept 15,
2004;61(1):12-25.
Makhoul I,
Esllinger P, Popescu D, Harvey H, Parkinson K, Lipton A. Effect
of aromatase inhibitor therapy on cognitive function. Proc of
ASCO 23:846, 2004. Abstract.
Makhoul I,
Curti B and Sachdeva K. Extragonadal germ cell
tumors. eMedicine, eMedicine Specialties: Medicine, OB/gyn,
Psychiatry, and Surgery: Hematology [Internet].June 30, 2004.
Available from http://www.emedicine.com/med/topic759.htm.
Makhoul I,
Claxton D, Rybka W. Pure B-Cell Disorders. eMedicine, eMedicine
Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery:
Hematology [Internet]. Aug 25, 2006. Available from:
http://www.emedicine.com/med/topic216.htm.
Makhoul I,
Harvey H, Makhoul H, Souba W. Breast cancer. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and
Surgery: Oncology [Internet].Sep20, 2006.
http://www.emedicine.com/med/topic2808.htm.
Makhoul I, Javeed M, Ballard J. Spur Cell Anemia. eMedicine, eMedicine
Specialites: Medicine, OB/Gyn, Psychiatry, and Surgery:
Hematology [Internet]. Aug 25, 2006. Available from:
http://www.emedicine.com/med/topic2163.htm.
Mamounas E,
Jeong J-H, Wickerham L, Smith R, Geyer C, Ganz P, Land S,
Hutchins L, Eisen A, Ingle J, Costantino J, Wolmark N. Benefit
from exemestane (EXE) as extended adjuvant therapy after 5 years
of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. 29th
Annual San Antonio Breast Cancer Symposium, Breast Cancer
Research and Treatment. 2006 December 14-17; 100:49. Abstract.
Mamounas
EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A,
Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG,
Kroener JF, Hutchins LF,
Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP,
Wolmark N. Benefit from exemestane as extended adjuvant therapy
after 5 years of adjuvant tamoxifen: intention-to-treat analysis
of the National Surgical Adjuvant Breast And Bowel Project B-33
trial.J Clin Oncol. 2008 Apr 20;26(12):1965-71. Epub 2008 Mar
10.
Mansoor M,
Ryan CJ, Makhoul I, Sachdeva K, Curti B. Germ Cell Tumors. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry,
and Surgery: Oncology[Internet]. July 27, 2006.
http://www.emedicine.com/med/topic863.htm.
Margulies
AG,
Makhoul I,
Henry-Tillman
R, Kepple J, Adkins L, Colvert M, Korourian S,
Klimberg VS.
Tumor
Burden in Neoadjuvant Sentinel Lymph Node Biopsy May Predict
Response to Chemotherapy. Am Surgical
Assoc Meeting 2005. Abstract.
McLaughlin P, Estey E, Glassman A,
Romaguera J, Samaniego F, Ayala A, Hayes K,
Maddox AM, Preti HA,
Hagemeister FB. Myelodysplasia and acute myeloid leukemia
following therapy for indolent lymphoma with fludarabine,
mitoxantrone, and dexamethasone (FND) plus rituximab and
interferon alpha. Blood 2005 Jun 15;105(12):4573-5. Epub
2005 Mar 1.
Mehta P,
Kaushal V. Effect of daclizumab for graft-versus-host disease
after bone marrow transplantation on lymphocyte-endothelial cell
interaction. Intl Soc Thromb and Haem. Sydney, Australia,
August 2005. Abstract.
Mehta P.
Poems on Cancer Education. J Cancer Educ 2006; 21(2):108-9.
Mehta P.
Chemotherapy induced neutropenia in the new millennium. Federal
Practitioner 2006; 23 (supplement 2) 2-3.
Mehta P.
He didn't have a chance. J Clin Oncol 2007 Aug
1;25(22):3378-9.
Mehta P.
Special Treatment: A commentary on "When Two Worlds Collide."
J Clin Oncology 2007; 25: 4018-9.
Mehta P,
Hester M, Safar AM, Thompson
R. Ethics-in-oncology forums. J Cancer Educ 2007
Fall;22(3):159-64.
Mehta P,
Nair B. TNF alpha inhibition and AML. Am J Hematol 2007
Dec 27; [Epub ahead of print]
Midathada MV,
Mehta P, Waner M, Fink LM. Recombinant factor VIIa
in the treatment of bleeding. Am J Clin Pathol 2004
Jan;121(1):124-37.
Midathada MV, Spencer T, Mack K,
Erkman L, Govindarajan R.
Influence of demographics on patient refusal to enroll into
clinical trials. Proc of ASCO 23(16S):6038, 2005.
Abstract.
Midathada M,
Mehta J, Govindarajan R, Safar AM, Hester DM,
Kyasa MJ,
Mehta P.
When substance abuse interferes with cancer treatment. Federal
Practitioner 2006; 23 (9): 39-51.
Monzavi-Karbassi B, Hennings LJ,
Artaud C, Liu T, Jousheghany F, Pashov A, Murali R,
Hutchins LF, Kieber-Emmons T. Preclinical studies of carbohydrate mimetic
peptide vaccines for breast cancer and melanoma. Vaccine 2007;
25(16):3022-31.
Nair BP and
Safar AM. Utilization of positron emission
tomography scans (PET) in the management of NSCLC at a center
with limited access to this imaging modality. Proc of ASCO
24(18S):6140, 2006. Abstract.
Nair B, Spencer T, Rival G,
Mehta P.
Correlation of content of
hemoglobin in reticulocytes (CHR) in hematologic disease. Blood
2006; 108: 5526. Abstract.
Nair B,
Mehta P. Pilot program of smoking cessation in patients with
smoking-related cancers. Accepted for poster presentation,
American Association of Cancer Education annual meeting, San
Diego, CA, October 2006. J Cancer Education 2006; 21 (suppl
2):40. Abstract.
Nair B,
Mehta P. Reviews of “Bone Marrow and Stem Cell
Transplantation” and “Renewing the Stuff of Life: Stem Cells,
Ethics and Public Policy,” JAMA 2007; 298: 1571.
Nair B, Raval G,
Mehta P. TNF-alpha inhibitor
etanercept and hematologic malignancies: report of a case and
review of the literature. Am J Hematol 2007
Nov;82(11):1022-4.
Nair BP, Khalil O, Phooshkooru VR,
Hutchins LF. Weight change
among breast cancer patients receiving chemotherapy: A
retrospective analysis. Proc of ASCO 25(18S): 19535,
2007.Abstract.
Nagarajan A, Mehta J,
Safar M, Thompson R,
Mehta P. Whent eh patient,
family, and physicians disagree about treatment. Fed Pract
2005;22(1):15-16, 18.
Norris LB
and Mehta P. The role of granulocyte growth factors.
Federal
Practitioner 2006; 23 (supplement 2) 16-25.
O’Day S, Gonzalez R, Lawson D, Weber
R, Hutchins L, Anderson C,
McLeod M, Hurwitz C, Haddad J, Jacobson E. Subgroup analysis of
efficacy and safety analysis of a randomized, double-blinded
controlled phase II study of STA-4783 in combination with
paclitaxel in patients with metastatic melanoma. Proc of ASCO
25(18S):8528, 2007. Abstract.
Piekarz R, Frye R, Wright J, Figg W,
Allen S, Kirschbaum M, Zain J, Hutchins
L, Showe L, Fojo T, Bates SE. Update of the NCI
multiinstitutional phase II trial of romidepsin, FK228, for
patients with cutaneous or peripheral T-cell lymphoma. Proc
of ASCO 25(18S):8027, 2007. Abstract.
Pierce LJ,
Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston
RB, Osborne CK, Albain KS. Sequencing of tamoxifen and
radiotherapy after breast-conserving surgery in early-stage
breast cancer. J Clin Oncol 2005 Jan 1;23(1):24-9. Epub
2004 Nov 15.
Prasad HK,
Govindarajan R. Heparin-induced skin necrosis
associated with thrombocytopenia and acquired protein C and
protein S deficiency. Am J Hematol 2007
Dec;82(12):1116-7.
Prasad HK, Kaushal V,
Mehta P. Isolated
thrombocytopenia induced by thalidomide in a patient with
multiple myeloma: case report and review of literature. Am J
Hematol 2007 Sep;82(9):855-7.
Raval GG, Wingard JR,
Mehta
P. Bone Marrow Transplantation, Long-Term Effects. eMedicine,
eMedicine Specialties: Pediatric: Oncology [Internet]. July 31,
2006.
http://www.emedicine.com/ped/topic2551.htm.
Safar AM
and Shwaiki A. The impact of platelet count (Pit#) on outcome in
curable non-small cell lung cancer (NSCLC). Proc of ASCO
23:9734, 2004. Abstract.
Safar AM,
Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD,
Hutchins LF, Fan CY.
Methylation profiling of archived non-small cell lung cancer: a
promising prognostic system. Clin Cancer Res 2005 Jun
15;11(12):4400-5.
Safar AM,
Al-Khasawneh K, Su X, White P, Fan C. Sputum methylation has low
specificity as diagnostic test for lung malignancy. Proc. ASCO
9633, 2005. Abstract.
Safar AM, Kyasa MJ,
Thompson R, Hester M,
Mehta P. Impact of ethics-in-oncology forums in a
Hematology Oncology Fellowship Program. Am Assoc Cancer Educ,
2005. Abstract.
Safar AM,
Spencer HJ, III, Su X, Hutchins LF,
Chun-Yang F. DNA methylation in lymph nodes of stage I NSCLC:
common finding devoid of prognostic impact. Proc. AACR 2769,
2005. Abstract.
Safar AM,
Macleod S, Klimberg V, Henry-Tillman R, Fan C,
Hutchins L, Makhoul I.
Hydralazine-demethylating systemic therapy for breast cancer.
Proc of ASCO 24(18S): 13131, 2006.Abstract.
Safar AM,
O'Sullivan P, Ray L, Hutchins L, Mehta P. Editorial clubs as a
new teaching tool in postgraduate training. J Cancer Educ 2006; 21(3):163-5.
Safar AM,
Spencer H, Su X, Cooney CA, Shwaiki A and Fan C-Y. Promoter
hypermethylation for molecular nodal staging in non–small cell
lung cancer. Arch Pathol Lab Med 2007; 131(6):936-941.
Shah RV, Gokden N, James J,
Kota M, Kohli M. Expression
of epidermal growth factor receptor (EGFR) in renal cell
neoplasms. Proc of ASCO 23(16S):9701, 2005. Abstract.
Schichman SA, McClure R, Schaefer RF,
Mehta P. HIV and
plasmablastic lymphoma manifesting in sinus, testicles, and
bones: a further expansion of the disease spectrum. Am J
Hematol 2004 Nov;77(3):291-5.
Sherman AC, Edwards D, Simonton S,
Mehta P. Caregiver stress
and burnout in an oncology unit. Palliat Support Care
2006 Mar;4(1):65-80.
Shwaiki A and
Safar AM. The impact of
platelet count (Plt#) on outcome in curable colon cancer.
Proc of ASCO 23:9735, 2004. Abstract.
Stephenson
J, Cohn A, Crawford J, Maddox A-M, Jones S, Lum P, Yang X, Amado
R, Burris H. Administration of panitumumab every two weeks (Q2W)
as a 30-min or 60-min infusion: Safety and pharmacokinetics (PK)
from a phase 1 study in patients with solid tumors.
ASCO GI
Proceedings 2007; January. Abstract.
Unger JM, Crowley JJ, Coltman CA,
Hutchins LF, Martino S,
MacDonald JS, Gandara DS, Crawford ED, Livingston RB, Albain KS.
Accrual patterns of the Southwest Oncology Group (SWOG) by sex,
race/ethnicity, and age: Updated and expanded analyses. Proc
of ASCO 23:6014, 2004. Abstract.
Unger JM, Coltman CA Jr., Drowley JJ,
Hutchins LF, Martino S,
Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED,
Albain KS. Impact of the year 2000 Medicare policy change on
older patient enrollment to cancer clinical trials. J Clin
Oncol 2006 Jan 1;24(1):141-4. Epub 2005 Dec 5.
Wang-Gillam A, Mehta J, Thompson R,
Safar M, Mehta P. When it’s
time to stop cancer treatment: Helping patients prepare for
death. Fed Pract 2005;22(4):14,16,22-23.
Wang-Gillam
A, Mehta P. IRB rotations to promote systems competency in
hematology/oncology fellowship training programs. J Cancer
Education 2006; 21(suppl 2): 24a.
Wang-Gillam
A, Miles DA, Hutchins L. Evaluation of vitamin D deficiency in
breast cancer patients on bisphosphonate therapy. 29th
Annual San Antonio Breast Cancer Symposium. 2006 December 14-17;
100:6098. Abstract.
Wang-Gillam A,
Mehta P. Review of “How Doctors Think”, JAMA 2007;
298: 688-689.Wang-Gillam A. Siegel E, Mayes D,
Hutchins L,
Zhou YH. Anti-tumor effect of doxycycline on gioblastoma
cells. J Cancer Molecules 2007 November
5;3(5)147-153.
Wang-Gillam
A, Miles DA, Hutchins LF.
Evaluation of vitamin D deficiency in breast cancer patients on
bisphosphonates.Oncologist. 2008 Jul;13(7):821-7. Epub 2008 Jul
9.
Wong JM,
Kyasa MJ, Hutchins L, Collins K. Telomerase RNA
deficiency in peripheral blood mononuclear cells in X-linked
dyskeratosis congenita. Hum Genet. 2004 Oct;115(5):448-55. Epub
2004 Sep 3.
|